However, BTZ alone or in combination with pemetrexed in previous studies did not significantly extend the overall survival in NSCLC patients (Scagliotti et al., 2010), indicating that specific treatment combinations may be required. This evidence concerns the gene CASC3 and non-small cell lung carcinoma.